Skip to content

Foundayo

Foundayo dosage — 0.8 mg to 17.2 mg explained

Six tablet strengths, one tablet a day

Last reviewed: September 2026

Foundayo (orforglipron) is a once-daily tablet. The FDA label starts at 0.8 mg and steps up to 2.5 mg, then 5.5 mg, with at least 30 days on each dose. The maximum is 17.2 mg. You can take it with or without food.

Your step-up schedule

You start at 0.8mg and step up after at least 30 days on each dose. From 5.5mg, further increases are optional and depend on how you respond and how you tolerate it.

  1. At least 30 days0.8mg

    The starting dose. The label has you stay on it for at least 30 days before stepping up.

  2. At least 30 days2.5mg

    The first step up, after at least 30 days on 0.8 mg.

  3. At least 30 days5.5mg

    The second step up, after at least 30 days on 2.5 mg. From here, each further increase is optional.

  4. Optional step up9mg

    Your prescriber can raise the dose after at least 30 days on the current one, based on how you respond and how you tolerate it.

  5. Optional step up14.5mg

    Another optional step, on the same terms: at least 30 days on the current dose first.

  6. Optional step up17.2mg

    The maximum dose the label allows, taken once daily with or without food.

    Maximum dose

This follows the Dosage and Administration section of the FDA label. Because each dose lasts at least 30 days, the earliest anyone could reach 9 mg is after about three months, and each further step adds at least 30 days. Your prescriber sets the pace.

See the full titration schedule with week-by-week expectations →

Starting dose vs maximum dose

The maximum dose is the highest approved dose — it is not the same as your maintenance dose.

Starting dose

0.8mg

Your first dose — the lowest to let your body adjust

Maximum dose

17.2mg

The highest approved dose — not everyone needs to reach it

From 5.5 mg onward, the label leaves each further increase to your prescriber, "based on treatment response and tolerability". The highest dose it allows is 17.2 mg once daily.

Weight loss at each dose

Average weight loss from the ATTAIN-1 trial, shown at the three tablet doses the label reports results for. The trial itself used a capsule at different strengths.

5.5mg7.8%
9mg9.3%
17.2mg12.4%
The trial capsule doses were 6, 12 and 36 mg. The FDA label shows these results as the equivalent tablet doses of 5.5, 9 and 17.2 mg. The label reports weight loss for these three doses only.Source: ATTAIN-1 trial (n=3,127, 72 weeks), people who kept taking it

What this means

In ATTAIN-1 (adults without type 2 diabetes, 72 weeks), people who kept taking Foundayo lost on average 7.8% of their body weight at 5.5 mg, 9.3% at 9 mg and 12.4% at 17.2 mg, compared with 0.9% on placebo. Counting everyone who started, whether or not they kept taking it, the averages were 7.5%, 8.4% and 11.2%, compared with 2.1% on placebo. These are group averages, not a prediction for any one person.

When your doctor might change your dose

Your dosing is flexible and tailored to your needs.

Tolerating well

The label allows the next step after at least 30 days on your current dose. Whether to go up is your prescriber’s decision.

Side effects notable

Talk to your prescriber about waiting longer. The 30 days is a minimum, not a fixed timetable.

Reached your goal

From 5.5 mg, each increase is optional, so moving to 17.2 mg is not automatic. Any decision to stay on a dose is for your prescriber.

Common questions

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Keep reading

Full Orforglipron overview →How to take it →Titration schedule →Side effects →

Next step most people take

Learn how to take itInjection technique or daily pill routineCheck side effectsWhat to expect and how to manage them

Built with agentic AI tools and not a substitute for medical advice

Last reviewed:

Was this page helpful?
Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. Prices shown are United States self-pay or list prices and vary by insurance and country.